Ben Fidler
Lead Editor | @BentheFidlerBen is a lead editor for BioPharma Dive. He is a veteran business journalist with more than 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
869 articles by Ben Fidler
-
Lilly boosts ADC portfolio with CrossBridge Bio deal
April 14, 2026 -
FDA again spurns Replimune melanoma drug
April 10, 2026 -
RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degraders
April 10, 2026 -
Sanofi immune drug hopeful posts mixed results in mid-stage tests
April 7, 2026 -
Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout
April 6, 2026 -
Rocket gene therapy cleared by FDA for rare immune disorder
March 27, 2026 -
Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug
March 25, 2026 -
FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares
March 23, 2026 -
Earendil Labs, an AI-powered drugmaker, hauls in $787M
March 20, 2026 -
Rhythm obesity drug wins broader use from FDA
March 20, 2026 -
Novo uses FDA voucher to win speedy approval of higher-dose Wegovy
March 19, 2026 -
AstraZeneca to boost cell therapy capabilities with new China investment
March 19, 2026 -
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy
March 16, 2026 -
Vertex kidney disease drug hits mark in late-stage study
March 9, 2026 -
Novo, Hims reach deal to sell GLP-1 drugs together
March 9, 2026 -
Vinay Prasad, controversial FDA leader, to again depart agency
March 6, 2026 -
FDA again targets GLP-1 compounders; Intellia to restart heart disease trial
March 4, 2026 -
Safety concerns spur Aardvark to halt key Prader-Willi drug trial
March 2, 2026 -
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA
Feb. 27, 2026 -
Sarepta CEO Doug Ingram to retire, with company at a crossroads
Feb. 26, 2026 -
Novo, searching for a spark, spotlights new data for three-pronged obesity drug
Feb. 24, 2026 -
Merck to split cancer, specialty drug businesses in leadership shakeup
Feb. 23, 2026 -
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy
Feb. 23, 2026 -
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
Feb. 20, 2026 -
Hims cancels plans to sell compounded GLP-1 pill after FDA backlash
Feb. 7, 2026
